mirna labeling, quality control, chip hybridization and microarray analysis (CapitalBio Corporation)
90
Structured Review
CapitalBio Corporation
mirna labeling, quality control, chip hybridization and microarray analysis
Mirna Labeling, Quality Control, Chip Hybridization And Microarray Analysis, supplied by CapitalBio Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mirna+microarray+data+analysis/mirna+labeling++quality+control++chip+hybridization+and+microarray+analysis/pmc05154343-155-17-5
Average 90 stars, based on 1 article reviews
Mirna Labeling, Quality Control, Chip Hybridization And Microarray Analysis, supplied by CapitalBio Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mirna+microarray+data+analysis/mirna+labeling++quality+control++chip+hybridization+and+microarray+analysis/pmc05154343-155-17-5
Average 90 stars, based on 1 article reviews
mirna labeling, quality control, chip hybridization and microarray analysis - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Labeling:Article Title: MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression Article Snippet: Total RNA was extracted from HeLa and CaSki cells and their paclitaxel-resistant counterparts using a Qiagen miRNeasy mini kit and following the manufacturer protocol. .. Total RNA was sent to CapitalBio Corporation (Beijing, China) for Article Title: miR-30a-5p enhances paclitaxel sensitivity in non-small cell lung cancer through targeting BCL-2 expression. Article Snippet: Lung cancer remains the leading cause of cancer-related death worldwide.. Paclitaxel, either as monotherapy or combined with other agents, is the standard treatment for advanced non-small cell lung cancer (NSCLC), the most common type of lung cancer.. However, both de novo and acquired resistance against paclitaxel frequently occurs and represents a huge clinical problem. Control:Article Title: MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression Article Snippet: Total RNA was extracted from HeLa and CaSki cells and their paclitaxel-resistant counterparts using a Qiagen miRNeasy mini kit and following the manufacturer protocol. .. Total RNA was sent to CapitalBio Corporation (Beijing, China) for Article Title: miR-30a-5p enhances paclitaxel sensitivity in non-small cell lung cancer through targeting BCL-2 expression. Article Snippet: Lung cancer remains the leading cause of cancer-related death worldwide.. Paclitaxel, either as monotherapy or combined with other agents, is the standard treatment for advanced non-small cell lung cancer (NSCLC), the most common type of lung cancer.. However, both de novo and acquired resistance against paclitaxel frequently occurs and represents a huge clinical problem. Hybridization:Article Title: MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression Article Snippet: Total RNA was extracted from HeLa and CaSki cells and their paclitaxel-resistant counterparts using a Qiagen miRNeasy mini kit and following the manufacturer protocol. .. Total RNA was sent to CapitalBio Corporation (Beijing, China) for Article Title: miR-30a-5p enhances paclitaxel sensitivity in non-small cell lung cancer through targeting BCL-2 expression. Article Snippet: Lung cancer remains the leading cause of cancer-related death worldwide.. Paclitaxel, either as monotherapy or combined with other agents, is the standard treatment for advanced non-small cell lung cancer (NSCLC), the most common type of lung cancer.. However, both de novo and acquired resistance against paclitaxel frequently occurs and represents a huge clinical problem. Microarray:Article Title: MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression Article Snippet: Total RNA was extracted from HeLa and CaSki cells and their paclitaxel-resistant counterparts using a Qiagen miRNeasy mini kit and following the manufacturer protocol. .. Total RNA was sent to CapitalBio Corporation (Beijing, China) for Article Title: miR-30a-5p enhances paclitaxel sensitivity in non-small cell lung cancer through targeting BCL-2 expression. Article Snippet: Lung cancer remains the leading cause of cancer-related death worldwide.. Paclitaxel, either as monotherapy or combined with other agents, is the standard treatment for advanced non-small cell lung cancer (NSCLC), the most common type of lung cancer.. However, both de novo and acquired resistance against paclitaxel frequently occurs and represents a huge clinical problem. |
